This technology includes monoclonal antibodies (mAb) that specifically and with high affinity bind the final complement components C3dg and C3d (subsequently referred to as C3d), which can be used to kill tumor cells that carry C3d on their cell surface. We show that tumor cells of patients treated with the therapeutic anti-CD20 mAb ofatumumab carry C3d on the cell surface and can bind and be killed by addition of anti-C3 mAbs. In contrast, further addition of more ofatumumab has only minimal effects.

This technology includes antibodies against TL 1A for the inhibition of TL 1A-DR3 interactions for the diagnosis and treatment of various autoimmune diseases. Through the use of our developed hamster anti-mouse and mouse anti-human monoclonal antibodies, we’ve demonstrated that treatment with anti-mouse TL 1A prevented collagen-induced arthritis and TNBS-induced colitis NEED TO UPDATE

This technology includes ten engineered human induced pluripotent stem cell (iPSC) lines with reported genes inserted into safe harbor sites for use in therapy and diagnostic screening assay development as well as basic stem cell biology research. These cell lines have the potential to differentiate into all cells in the body, and theoretically can proliferate/self-renew indefinitely.

This technology includes three distinct cell lines of motor neuron progenitors, derived from different sources: human induced pluripotent stem cell (iPSC) line BC1, human iPSC line X1, and human embryonic stem cell (hESC) line H14. These cell lines hold significant potential for multiple diagnostic and therapeutic applications. A key advantage of these cell lines is the commercial availability of their starting materials (iPSC-BC1, iPSC-X1, and hESC-H14), which are not restricted in terms of usage of their derivatives.

This technology includes the development of a mouse line capable of producing single-chain antibodies (nanobodies). Nanobodies, identified initially from Camelidae (including llamas and camels) but also found in cartilaginous fish, consist of a single variable heavy chain domain (VHH) that binds to specific epitopes. Nanobodies have equivalent binding specificity to antigens as antibodies but are more heat- and detergent-stable.

This technology includes AAVS1 and C13 “safe harbor” transcription activator-life effector nucleases (TALENs) for drug screening or gene therapy applications. TALENs are engineered sequence-specific DNA endonucleases that can significantly enhance genome-editing efficiency by >100-1000 folds. “Safe harbor” such as AAVS1 safe harbor and C13 safe harbor is genome locus that allows robust and persistent transgene expression with no or minimal interference of endogenous gene expression and cell properties.

This technology includes an IgA antibody, specifically designed to target the receptor binding domain of SARS-CoV-2, the virus causing COVID-19. Administered intranasally, this antibody has potential neutralizing activity, aiming to prevent COVID-19. IgA, an antibody class present in mucosal areas, plays a crucial role in immune defense at the initial site of viral infection. The primary application of this technology is envisioned as a therapeutic nasal spray, intended to prevent SARS-CoV-2 infection, particularly in high-risk populations.

This technology includes anti-PSMA antibody labeled with 177Lu, which has shown to be an effective treatment for prostate cancer. Several small molecules targeting PSMA were also evaluated in prostate cancer patients labeled with betta emitters such as 177Lu. The most common one is 177Lu-PSMA-617 which is under clinical evaluation in many countries. Usual treatment in patients in most clinical trials was composed of up to 3 cycles of 177Lu-PSMA-617.

This technology includes the use of atorvastatin, a medication to manage hypercholesterolemia, as a method to protect patients receiving cisplatin from hearing loss. Cisplatin chemotherapy is indicated in various cancer types in adults and children and is known to cause hearing loss. A patient on atorvastatin during chemotherapy is 46% less likely to acquire a significant cisplatin-induced hearing loss relative to a non-statin user. Atorvastatin is an FDA-approved medication routinely prescribed and well-tolerated clinically.

This technology includes a method to identify potentially therapeutic microRNAs in cancer, particularly squamous cell carcinoma of the head and neck (HNSCC). This approach first utilizes a large and publicly available expression dataset, which is then validated by a smaller independent dataset to determine deregulated microRNAs expression. These results are then intersected with in vitro functional anti-proliferative screening data to select for microRNAs that play a functional tumor suppressive role and likely serve as therapeutic targets.